Using Osteoporosis Therapies in Combination

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2017 Jul 2

PMID 28667435

Citations 15

Authors

Michael R McClung

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The objective of this review is to update evidence regarding the use of osteoporosis drugs in sequence or in combination to optimize increases in bone mass and strength.

Recent Findings: Simultaneous use of denosumab plus teriparatide produces larger increases in BMD than does monotherapy. The use of bisphosphonates or denosumab after teriparatide results in progressive gains in BMD. When switching from bisphosphonates and especially denosumab to teriparatide, an overlap of 6-12 months may prevent the transient loss of BMD in cortical sites. Phase 3 trials document fracture risk reduction with anabolic therapy for 12-18 months followed by an anti-remodeling drug. With the exception of adding teriparatide to ongoing denosumab therapy, there is little evidence to support the use of more than one osteoporosis drug at a time. In contrast, sequential therapy regimens of anabolic drugs followed by potent anti-remodeling agents will be the new standard for treating patients at imminent risk of fracture.

Citing Articles

Insights and implications of sexual dimorphism in osteoporosis.

Zhang Y, Xie N, Sun X, Nice E, Liou Y, Huang C Bone Res. 2024; 12(1):8.

PMID: 38368422 PMC: 10874461. DOI: 10.1038/s41413-023-00306-4.

Heraclenin promotes the osteogenic differentiation of bone marrow stromal cells by activating the RhoA/ROCK pathway.

Yu Z, Yuan J, Yu Y Histol Histopathol. 2024; 39(8):1065-1077.

PMID: 38258549 DOI: 10.14670/HH-18-702.

Pathophysiology and Therapeutic Management of Bone Loss in Patients with Critical Illness.

Kim T, Kim H Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139844 PMC: 10747168. DOI: 10.3390/ph16121718.

[Lipocalin 2 induces self-limited inhibition of osteoblast differentiation of mesenchymal stem cells].

Chen Z, Li S, Zhang Y, Yang W, Wang T Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(8):1339-1344.

PMID: 37712270 PMC: 10505573. DOI: 10.12122/j.issn.1673-4254.2023.08.10.

Mechanistic advances in osteoporosis and anti-osteoporosis therapies.

Wang H, Luo Y, Wang H, Li F, Yu F, Ye L MedComm (2020). 2023; 4(3):e244.

PMID: 37188325 PMC: 10175743. DOI: 10.1002/mco2.244.

References

Finkelstein J, Wyland J, Lee H, Neer R . Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010; 95(4):1838-45. PMC: 2853981. DOI: 10.1210/jc.2009-1703. View

Heiss G, Wallace R, Anderson G, Aragaki A, Beresford S, Brzyski R . Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008; 299(9):1036-45. DOI: 10.1001/jama.299.9.1036. View

Walker M, Cusano N, Sliney Jr J, Romano M, Zhang C, McMahon D . Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine. 2012; 44(1):237-46. DOI: 10.1007/s12020-012-9819-4. View

Cosman F, Nieves J, Dempster D . Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. J Bone Miner Res. 2016; 32(2):198-202. DOI: 10.1002/jbmr.3051. View

Leder B, Tsai J, Uihlein A, Burnett-Bowie S, Zhu Y, Foley K . Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014; 99(5):1694-700. PMC: 4010689. DOI: 10.1210/jc.2013-4440. View

Harris S, Eriksen E, Davidson M, Ettinger M, Moffett Jr A, Baylink D . Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001; 86(5):1890-7. DOI: 10.1210/jcem.86.5.7505. View

Wasnich R, Bagger Y, Hosking D, McClung M, Wu M, Mantz A . Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause. 2004; 11(6 Pt 1):622-30. DOI: 10.1097/01.gme.0000123641.76105.b5. View

Cosman F, Wermers R, Recknor C, Mauck K, Xie L, Glass E . Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009; 94(10):3772-80. DOI: 10.1210/jc.2008-2719. View

Cosman F, Eriksen E, Recknor C, Miller P, Guanabens N, Kasperk C . Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2010; 26(3):503-11. DOI: 10.1002/jbmr.238. View

10.

Miller P, Pannacciulli N, Brown J, Czerwinski E, Nedergaard B, Bolognese M . Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab. 2016; 101(8):3163-70. PMC: 4971333. DOI: 10.1210/jc.2016-1801. View

11.

Cauley J, Robbins J, Chen Z, Cummings S, Jackson R, LaCroix A . Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290(13):1729-38. DOI: 10.1001/jama.290.13.1729. View

12.

Cosman F, Miller P, Williams G, Hattersley G, Hu M, Valter I . Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017; 92(2):200-210. DOI: 10.1016/j.mayocp.2016.10.009. View

13.

Black D, Greenspan S, Ensrud K, Palermo L, McGowan J, Lang T . The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349(13):1207-15. DOI: 10.1056/NEJMoa031975. View

14.

Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V . Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16(5):925-31. DOI: 10.1359/jbmr.2001.16.5.925. View

15.

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H . Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res. 2012; 28(1):196-205. DOI: 10.1002/jbmr.1716. View

16.

Schafer A, Sellmeyer D, Palermo L, Hietpas J, Eastell R, Shoback D . Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab. 2012; 97(10):3522-9. PMC: 3674294. DOI: 10.1210/jc.2012-1844. View

17.

Min Y, Lee D, Choi S, Kim J, Choi D, Yoon B . Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial. Menopause. 2013; 20(7):761-6. DOI: 10.1097/GME.0b013e31827b24af. View

18.

Lindsay R, Nieves J, Formica C, HENNEMAN E, Woelfert L, Shen V . Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350(9077):550-5. DOI: 10.1016/S0140-6736(97)02342-8. View

19.

Recknor C, Czerwinski E, Bone H, Bonnick S, Binkley N, Palacios S . Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013; 121(6):1291-1299. DOI: 10.1097/AOG.0b013e318291718c. View

20.

Tsai J, Uihlein A, Lee H, Kumbhani R, Siwila-Sackman E, McKay E . Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013; 382(9886):50-6. PMC: 4083737. DOI: 10.1016/S0140-6736(13)60856-9. View